Kosteneffectiviteit van transfusiealternatieven
Hematologie
Early intravenous iron administration in the Emergency Department reduces red blood cell unit transfusion, hospitalisation, re-transfusion, length of stay and costs. (opent nieuw venster)
Bron: Blood Transfus 2020;18(2):106-16.
Geïndexeerd: PubMed 31855149
DOI: 10.2450/2019.0248-19
https://www.ncbi.nlm.nih.gov/pubmed/31855149 (opent nieuw venster)
Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe. (opent nieuw venster)
Bron: Support Care Cancer 2013;21(2):485-93.
Geïndexeerd: PubMed 22825456
DOI: 10.1007/s00520-012-1538-0
https://www.ncbi.nlm.nih.gov/pubmed/22825456 (opent nieuw venster)
Restrictive blood transfusion practices are associated with improved patient outcomes. (opent nieuw venster)
Bron: Transfusion 2014;54(10 Pt 2):2753-9.
Geïndexeerd: PubMed 24995770
DOI: 10.1111/trf.12723
https://www.ncbi.nlm.nih.gov/pubmed/24995770 (opent nieuw venster)
Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United Kingdom. (opent nieuw venster)
Bron: Clin Ther 2010;32(14):2478-93.
Geïndexeerd: PubMed 21353116
DOI: 10.1016/j.clinthera.2011.01.011
https://www.ncbi.nlm.nih.gov/pubmed/21353116 (opent nieuw venster)
Recombinant activated factor VII use in critically ill infants with active hemorrhage. (opent nieuw venster)
Bron: J Pediatr Surg 2008;43(12):2235-8.
Geïndexeerd: PubMed 19040942
DOI: 10.1016/j.jpedsurg.2008.08.053
https://www.ncbi.nlm.nih.gov/pubmed/19040942 (opent nieuw venster)
Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia. (opent nieuw venster)
Bron: Blood Adv. 2022;6(3):785-92.
Geïndexeerd: PubMed 34781363
DOI: 10.1182/bloodadvances.2021005627
https://pubmed.ncbi.nlm.nih.gov/34781363/ (opent nieuw venster)
Blood use in patients receiving intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation: the impact of a health system-wide patient blood management program. (opent nieuw venster)
Bron: Transfusion 2017;57(9):2189-96.
Geïndexeerd: PubMed 28671296
DOI: 10.1111/trf.14191
https://www.ncbi.nlm.nih.gov/pubmed/28671296 (opent nieuw venster)
Impact of a conservative red blood cell transfusion strategy in children undergoing hematopoietic stem cell transplantation. (opent nieuw venster)
Bron: Biol Blood Marrow Transplant 2012;18(5):813-7.
Geïndexeerd: PubMed 22080050
DOI: 10.1016/j.bbmt.2011.10.043
https://www.ncbi.nlm.nih.gov/pubmed/22080050 (opent nieuw venster)
The cost of blood: a study of the total cost of red blood cell transfusion in patients with β-thalassemia using time-driven activity-based costing. (opent nieuw venster)
Bron: Transfusion 2019;59(11):3386-95.
Geïndexeerd: PubMed 31664712
DOI: 10.1111/trf.15558
https://www.ncbi.nlm.nih.gov/pubmed/31664712 (opent nieuw venster)
Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. (opent nieuw venster)
Bron: Transfusion 2015;55(12):2807-15.
Geïndexeerd: PubMed 26264557
DOI: 10.1111/trf.13260
https://www.ncbi.nlm.nih.gov/pubmed/26264557 (opent nieuw venster)
Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (opent nieuw venster)
Bron: Cancer 2013;119(1):107-14.
Geïndexeerd: PubMed 22744794
DOI: 10.1002/cncr.27686
https://www.ncbi.nlm.nih.gov/pubmed/22744794 (opent nieuw venster)
Budget impact analysis on erythropoiesis-stimulating agents use for the management of chemotherapy-induced anaemia in Greece. (opent nieuw venster)
Bron: Cost Eff Resour Alloc 2013;11(1):16.
Geïndexeerd: PubMed 23870502
DOI: 10.1186/1478-7547-11-16
https://www.ncbi.nlm.nih.gov/pubmed/23870502 (opent nieuw venster)
Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (opent nieuw venster)
Bron: Support Care Cancer 2012;20(1):159-65.
Geïndexeerd: PubMed 21359879
DOI: 10.1007/s00520-010-1083-7
https://www.ncbi.nlm.nih.gov/pubmed/21359879 (opent nieuw venster)
Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada. (opent nieuw venster)
Bron: J Med Econ 2013;16(2):318-26.
Geïndexeerd: PubMed 23216012
DOI: 10.3111/13696998.2012.756400
https://www.ncbi.nlm.nih.gov/pubmed/23216012 (opent nieuw venster)
Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study. (opent nieuw venster)
Bron: Hematology 2018;23(7):417-22.
Geïndexeerd: PubMed 29157136
DOI: 10.1080/10245332.2017.1404262
https://www.ncbi.nlm.nih.gov/pubmed/29157136 (opent nieuw venster)
The burden of blood transfusion: a utilization and economic analysis--a pilot study in patients with chemotherapy-induced anemia (CIA). (opent nieuw venster)
Bron: J Med Econ 2013;16(5):633-8.
Geïndexeerd: PubMed 23425291
DOI: 10.3111/13696998.2013.778269
https://www.ncbi.nlm.nih.gov/pubmed/23425291 (opent nieuw venster)
Prospective monitoring of plasma and platelet transfusions in a large teaching hospital results in significant cost reduction. (opent nieuw venster)
Bron: Transfusion 2010;50(2):487-92.
Geïndexeerd: PubMed 19804569
DOI: 10.1111/j.1537-2995.2009.02413.x
https://www.ncbi.nlm.nih.gov/pubmed/19804569 (opent nieuw venster)
Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. (opent nieuw venster)
Bron: Am J Hematol 2010;85(10):795-7.
Geïndexeerd: PubMed 20645429
DOI: 10.1002/ajh.21772
https://www.ncbi.nlm.nih.gov/pubmed/20645429 (opent nieuw venster)
Increased hospital costs associated with red blood cell transfusion. (opent nieuw venster)
Bron: Transfusion 2015;55(5):1082-9.
Geïndexeerd: PubMed 25488623
DOI: 10.1111/trf.12958
https://www.ncbi.nlm.nih.gov/pubmed/25488623 (opent nieuw venster)